JP Morgan Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $575
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on IDEXX Laboratories but lowers the price target from $630 to $575.
October 11, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan has maintained its Overweight rating on IDEXX Laboratories but reduced the price target from $630 to $575, indicating a more cautious outlook.
The maintenance of an Overweight rating suggests continued confidence in IDEXX Laboratories' performance, but the lowered price target indicates a more cautious outlook, likely due to revised expectations or market conditions. This could lead to a short-term negative impact on the stock price as investors adjust to the new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100